TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 2, 2012, Pages 273-279

  Samimi, Goli ^a,b   Ring, Brian Z ^e   Ross, Doug T ^e   Seitz, Robert S ^e   Sutherland, Robert L ^a,b   O'Brien, Philippa M ^a   Hacker, Neville F ^c,d   Huh, Warner K ^f  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT'S CLINIC   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL HOSPITAL FOR WOMEN   (Australia)

^e Clarient Inc   (United States)

^f University of Alabama   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLATINUM DERIVATIVE; REPRESSOR PROTEIN; TRANSDUCIN LIKE ENHANCER OF SPLIT 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CO-REPRESSOR PROTEINS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84857099787     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0917     Document Type: Article

References (21)

1. Jennings BH, Ish-Horowicz D. The Groucho/TLE/Grg family of transcriptional co-repressors. Genome Biol 2008;9:205.
2. Hasson P, Egoz N, Winkler C, Volohonsky G, Jia S, Dinur T, et al. EGFR signaling attenuates Groucho-dependent repression to antagonize Notch transcriptional output. Nat Genet 2005;37:101-5. (Pubitemid 40070947)
3. Hasson P, Paroush Z. Crosstalk between the EGFR and other signalling pathways at the level of the global transcriptional corepressor Groucho/TLE. Br J Cancer 2007;96 Suppl:R21-5.
4. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006;24: 3039-47. (Pubitemid 46638938)
5. Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, HwangH, Khoury T, et al. TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res 2009;11:R17.
6. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351: 2519-29.
7. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24. (Pubitemid 38121593)
8. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007;82: 751-70. (Pubitemid 46878099)
9. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355: 1176-8. (Pubitemid 30172946)
10. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-8.
11. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410. (Pubitemid 44336908)
12. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
13. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008;18:954-62.
14. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT, et al. Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 2002;160:1229-38. (Pubitemid 34411627)
15. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-33. (Pubitemid 46518315)
16. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of betacatenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61:8247-55. (Pubitemid 33091619)
17. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000;287:1606-9. (Pubitemid 30127755)
18. Salinas PC. Modulation of the microtubule cytoskeleton: a role for a divergent canonical Wnt pathway. Trends Cell Biol 2007;17:333-42. (Pubitemid 47102199)
19. Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, et al. Prognostic significance of mucin and p53 expression in stage IB nonsmall cell lung cancer: a laboratory companion study toCALGB9633. J Thorac Oncol 2010;5:810-7.
20. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, et al. p53 Expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 trial (159905). Clin Cancer Res 2011;17:5170-8.
21. Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, et al. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 2009;27:4287-92.